Delving into the Latest Updates on AG-011 with Synapse

Overview

Basic Info

Drug Type

Interleukins

Synonyms

IL-10 (nonglycosylated), Interleukin-10

+ [2]

Target

IL-10R

Mechanism

IL-10 replacements(Interleukin-10 replacements)

Therapeutic Areas

Immune System DiseasesDigestive System Disorders

Active Indication-

Inactive Indication

Colitis, UlcerativeCrohn DiseaseUlcerative colitis, active moderate

Originator Organization

Intrexon ActoBiotics NV

Active Organization-

Inactive Organization

Intrexon ActoBiotics NV

Drug Highest PhaseDiscontinuedPhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Sequence Code 33955708

This study aimed to assess the correlation between the interleukin-10 (IL-10)-1082A/G polymorphism and idiopathic recurrent miscarriage (IRM) of Chinese Han. A total of 100 women with IRM and 100 control women with a successful pregnancy will be included in this study. Then genotyping will be performed.

Start Date01 Aug 2015

Sponsor / Collaborator-

NCT00729872

/ CompletedPhase 1/2

A Phase 2a Randomized, Placebo-Controlled, Double-Blind, Multi-Center Dose Escalation Study, to Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of AG011, in Subjects With Moderately Active Ulcerative Colitis

The purpose of this study is to verify the safety and tolerability of AG011 (genetically modified L. lactis that has been engineered to secrete human Interleukin-10), and to determine whether AG011 can successfully treat the symptoms of moderately active Ulcerative Colitis (UC).

Start Date01 Jul 2008

Sponsor / Collaborator

Intrexon ActoBiotics NV

EUCTR2008-000967-40-BE

/ Not yet recruitingNot Applicable

A Phase 2a Randomized, Placebo-Controlled, Double-Blind, Multi-Center Dose Escalation Study, to Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of AG011, in Subjects with Moderately Active Ulcerative Colitis

Start Date13 Jun 2008

Sponsor / Collaborator-

100 Clinical Results associated with AG-011

Login to view more data

100 Translational Medicine associated with AG-011

Login to view more data

100 Patents (Medical) associated with AG-011

Login to view more data

473

Literatures (Medical) associated with AG-011

01 Jul 2024·Cancer Communications

Interleukin‐10 gives exhausted chimeric antigen receptor (CAR) T cells a second breath

Article

Author: Heuser-Loy, Christoph

01 May 2024·Oral Diseases

Osteogenic effect and mechanism of IL‐10 in diabetic rat jaw defect mode

Article

Author: Lv, Menghao ; Hu, Sitong ; Ma, Pan ; Bai, Wei ; Yu, Shujia ; Zhu, Yihui ; Wang, Yihu ; Guo, Yanchuan

AbstractObjectiveThe aim of this study was to investigate the effect of IL‐10 on the phenotype polarization of macrophages and osteogenesis in diabetes mellitus type 2 (T2DM) rat jaw defects.MethodsLipopolysaccharide (LPS) and interleukin‐10 (IL‐10) were chosen to induce the polarization of macrophages. In vitro assessment included wound‐healing assay, western blotting, and alizarin red staining after co‐culture of the bone marrow‐derived mesenchymal stem cells (BMSCs) and induced macrophages. For in vivo study, IL‐10 was loaded on GelMA‐Heparin and applied to bone defects of the alveolar ridge in diabetic rats, while Bio‐Oss Collagen, simple GelMA‐Heparin, and blank control groups were set for contrast experiment. The mandibles of rats were processed for micro‐computed tomography, histology, and immunohistochemistry 1 week and 4 weeks after the operation.ResultsIL‐10 induced expression of arginase 1, TGF‐β1, EGR2, and Mannose Receptor (CD206), whereas LPS induced expression of iNOS, TNF‐α, IL‐6, CD80. The BMSCs co‐cultured with macrophages induced by IL‐10 showed increased migration, osteogenic differentiation, and mineralization in vitro. Notably, the IL‐10‐laden GelMA‐Heparin group showed quicker new bone formation and a higher M2/M1 ratio of macrophages in the jawbone defect area compared with the control groups.ConclusionsIL‐10 can stably induce macrophages to M2 type, thereby influencing BMSCs and improving the osteogenesis of jaw bone defects.

01 Apr 2024·Annals of Vascular Surgery

A Novel Method for the Rat Model of Abdominal Aortic Aneurysm Induced by Retroperitoneal Implantation of an Osmotic Pump System With Lipopolysaccharide

Article

Author: Wei, Ren ; Zhang, Hong-Peng ; Guo, Wei ; Gao, Jiang-Ping

BACKGROUNDFew methods can cocurrently mimic the pathological characteristics and nature history of human abdominal aortic aneurysms (AAAs), especially for the exist of the self-healing tendency of rodents. This study tested a novel method for the AAA rat model induced by retroperitoneal implantation of an osmotic pump system with lipopolysaccharide (LPS) based on the hypothesis that chronic inflammation of perivascular adipose tissue directly influenced the development and progression of AAAs.METHODS20 male Sprague-Dawley rats (10-month-old) fed with the Paigen diet were randomly divided into 4 groups: the blank group ×2, the sham group ×4, the empty capsule group ×4, and the LPS capsule group ×10. The LPS capsule group received implantations of the ALZET® osmotic pump capsule with LPS (3.6 μg/day) parallel to the abdominal aorta through a retroperitoneal approach. Two weeks later, 6 rats were randomly selected from the LPS capsule group to form the anti-inflammatory group and received implantations of another osmotic pump capsule with interleukin (IL)-10 (75 ng/day) through the same approach. The changes in abdominal aortic diameter were observed by ultrasound every 2 weeks, and samples were harvested for histopathologic and immunohistochemical analysis 6 weeks later.RESULTSWithin the 6 weeks after modeling, the LPS capsule group showed sustained and significant aortic dilatation (P < 0.01), while the anti-inflammatory group showed a rapid and obvious shrinkage 2 weeks after the IL-10 osmotic pump capsule implantation (P < 0.01). The LPS capsule group presented excellent pathological mimicking of human AAAs and showed severe medial degeneration with the least elastic content among the 5 groups at the end of the sixth week (P < 0.05). Notably, the anti-inflammatory group showed perfect medial preservation with the most elastic content (P < 0.05) and the highest elastin/collagen ratio (P < 0.01) at the end of the study. Matrix metalloproteinases (MMP) 2 and 9 and toll-like receptor 2 showed strong expression in the LPS capsule group at the end of the sixth week, which was significantly higher than that in the blank group and sham group. Interestingly, the anti-inflammatory group showed a slightly higher MMP9 expression than the LPS capsule group though there was no statistical difference between them.CONCLUSIONSThis novel method for the rat AAA model induced by retroperitoneal implantation of an osmotic pump capsule with LPS can concurrently mimic the histological characteristics and natural history of human AAAs. Further studies were needed to improve the osmotic pump system.

100 Deals associated with AG-011

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB12880

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Colitis, Ulcerative	Phase 2	BE	Intrexon ActoBiotics NV	01 Jul 2008
Colitis, Ulcerative	Phase 2	CA	Intrexon ActoBiotics NV	01 Jul 2008
Colitis, Ulcerative	Phase 2	SE	Intrexon ActoBiotics NV	01 Jul 2008
Colitis, Ulcerative	Phase 2	NL	Intrexon ActoBiotics NV	01 Jul 2008
Ulcerative colitis, active moderate	Phase 2	BE	Intrexon ActoBiotics NV	01 Jul 2008
Ulcerative colitis, active moderate	Phase 2	SE	Intrexon ActoBiotics NV	01 Jul 2008
Ulcerative colitis, active moderate	Phase 2	NL	Intrexon ActoBiotics NV	01 Jul 2008
Ulcerative colitis, active moderate	Phase 2	CA	Intrexon ActoBiotics NV	01 Jul 2008
Crohn Disease	Phase 2	-	-	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ERS2018	Not Applicable	-	-	Interleukin-10	tdgfzobzxd(rphfssvebo) = qcnyjntkko oevoejxxgr (pdepkwwnjt ) View more	-	15 Sep 2018
ERS2018	Not Applicable	-	-	Interleukin-10	nrfaagyfso(vtgvxccebl) = bwvgrhfilo xmjtlmixwn (xkmykfybyg ) View more	-	15 Sep 2018
ECCO2016	Not Applicable	-	-	Interleukin-10 (IL-10R-deficient patient)	syiwmtzlib(utlgjmedfd) = wzlntglcqh guctuhreok (bjuhwlcwlr ) View more	-	12 Feb 2016
AAAAI2006	Not Applicable	IL-4- \| IL-13 \| IL-10	20	IL-10	iemjavsszs(qaqupqtntn) = kkqeqfrjjd kbdpoyxwzq (mabmscgscs ) View more	Positive	01 Feb 2006
AAAAI2006	Not Applicable	IL-4- \| IL-13 \| IL-10	20	No IL-10	iemjavsszs(qaqupqtntn) = xfkmvdjikp kbdpoyxwzq (mabmscgscs ) View more	Positive	01 Feb 2006
ARVO2003	Not Applicable	Ganglion Cysts	-	IL-10	lctllfxyaz(hjlzwxdfyc) = urmfmkspkg dxbgektnvy (exklerfubn )	-	01 May 2003